ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

176
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
Refresh
23 Dec 2018 09:35

Last Week in Event SPACE: Familymart, Takeda, Harbin Electric, Motherson, Young Poong, NTT

Last Week in Event SPACE ... Bad banker analysis as Familymart Uny Holdings (8028 JP)'s tender for Don Quijote Holdings (7532 JP) doesn't even get...

Logo
1.1k Views
Share
17 Dec 2018 11:06

Discover HK Connect: Mainlanders Are Buying Shandong Gold, and Pharmaceuticals (2018-12-17)

In our Discover HK Connect series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed by...

Logo
438 Views
Share
27 Nov 2018 05:23

EM Health Care:  Late Cycle Rotation

Emerging Market Health Care allocations sit towards the lower end of their 7-year range. Current levels are off their 2015 highs by a margin, with...

Logo
339 Views
Share
22 Jul 2018 16:09

Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation

Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...

Logo
746 Views
Share
26 Jun 2018 15:55

Trade Risks Start to Impact, as China Biotech Ambitions Grow…

Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...

Logo
129 Views
Share
x